Qiagen NV (QGEN)
43.28
+0.94
(+2.22%)
USD |
NYSE |
Jun 17, 12:55
Qiagen Cash from Financing (Quarterly): -292.09M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -292.09M |
| December 31, 2023 | -7.436M |
| September 30, 2023 | -401.09M |
| June 30, 2023 | -15.47M |
| March 31, 2023 | -9.828M |
| December 31, 2022 | -546.37M |
| September 30, 2022 | 408.02M |
| June 30, 2022 | 23.21M |
| March 31, 2022 | -10.66M |
| December 31, 2021 | -30.97M |
| September 30, 2021 | -75.92M |
| June 30, 2021 | -2.626M |
| March 31, 2021 | -40.85M |
| December 31, 2020 | -92.92M |
| September 30, 2020 | 59.19M |
| June 30, 2020 | -25.78M |
| March 31, 2020 | 9.386M |
| December 31, 2019 | -102.83M |
| September 30, 2019 | -2.153M |
| June 30, 2019 | -53.70M |
| March 31, 2019 | -480.40M |
| December 31, 2018 | 427.95M |
| September 30, 2018 | -42.17M |
| June 30, 2018 | -23.18M |
| March 31, 2018 | -2.193M |
| Date | Value |
|---|---|
| December 31, 2017 | 1.202M |
| September 30, 2017 | 337.64M |
| June 30, 2017 | 292.80M |
| March 31, 2017 | -244.45M |
| December 31, 2016 | 5.229M |
| September 30, 2016 | -10.87M |
| June 30, 2016 | -0.992M |
| March 31, 2016 | -3.971M |
| December 31, 2015 | 3.607M |
| September 30, 2015 | 0.586M |
| June 30, 2015 | -80.46M |
| March 31, 2015 | -182.35M |
| December 31, 2014 | -37.69M |
| September 30, 2014 | -15.00M |
| June 30, 2014 | -30.89M |
| March 31, 2014 | 276.43M |
| December 31, 2013 | -18.98M |
| September 30, 2013 | -4.833M |
| June 30, 2013 | -4.829M |
| March 31, 2013 | -40.12M |
| December 31, 2012 | 145.02M |
| September 30, 2012 | 3.588M |
| June 30, 2012 | 66.76M |
| March 31, 2012 | 11.24M |
| December 31, 2011 | -243.90M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-546.37M
Minimum
Dec 2022
408.02M
Maximum
Sep 2022
-60.54M
Average
-20.63M
Median
Cash from Financing (Quarterly) Benchmarks
| MoonLake Immunotherapeutics | 50.98M |
| LENZ Therapeutics Inc | 171.27M |
| Thermo Fisher Scientific Inc | -1.821B |
| argenx SE | -- |
| uniQure NV | 0.00 |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 133.08M |
| Cash from Investing (Quarterly) | 6.431M |
| Free Cash Flow | 357.85M |
| Free Cash Flow Per Share (Quarterly) | 0.418 |
| Free Cash Flow to Equity (Quarterly) | 101.18M |
| Free Cash Flow to Firm (Quarterly) | 94.72M |
| Free Cash Flow Yield | 3.68% |